Promega unveils post-doctoral program

Promega, along with the multinational pharmaceutical firm AstraZeneca, have announced a partnership to create a post-doctoral research program to study the genes that cause certain diseases, according to a report from Wisconsin State Journal. The companies hope to gain insight into gene editing that is showing promise in curing diseases such as sickle cell anemia. The new partnership between Promega and AstraZeneca will create an inaugural program in which a team of about four to six scientists will research and develop gene-editing technology.